Literature DB >> 15757962

Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives.

A Spoorenberg1, A van Tubergen, R Landewé, M Dougados, S van der Linden, H Mielants, H van de Tempel, D van der Heijde.   

Abstract

OBJECTIVE: There is no "gold standard" to assess disease activity in patients with ankylosing spondylitis (AS). It is known that patients and physicians have different opinions about disease activity. The objective was therefore to investigate on which criteria patients with AS and physicians base their judgement on disease activity.
METHODS: A cohort of 203 AS out-patients fulfilling the modified New York criteria included in the ongoing long-term follow-up was analysed. The Assessment in Ankylosing Spondylitis (ASAS) International Working Group has established different domains relevant for outcome in AS. Each domain includes a number of instruments for making assessments, and all these instruments are included in the Outcome in Ankylosing Spondylitis International Study and were made every 6 months for 2 yr. Disease activity from the patient perspective as well as from the physician perspective was analysed using the patient's or the physician's global assessment of disease activity [visual analogue scale (VAS): 0 (best)-10 (worst)] by dichotomizing into "high disease activity" (VAS > or = 6.0) and "low disease activity" (VAS < or = 4.0). Data reduction by principal components analysis (PCA) was performed to distinguish factors capturing correlated instruments. Discriminant analysis with the factor loadings was performed to discriminate between a low and a high disease activity state from both the patient's and the physician's perspective. Multiple regression analysis on the discriminant scores was performed to prioritize the instruments.
RESULTS: PCA revealed four factors: spinal mobility, physician assessments, patient assessments and laboratory assessments (Cronbach's alpha 0.52-0.80; explained variance 61%). Discriminant function analysis showed that the factor "patient assessments" was most important (pooled correlation 0.85) in discriminating between a low and a high disease activity state as defined by the patient. The other three factors contributed marginally (pooled correlation <0.30). In contrast, the factors "physician's assessments" (pooled correlation 0.62), "spinal mobility" (pooled correlation 0.52) and "laboratory assessments" (pooled correlation 0.48) contributed most to the physician's perspective. The factor "patient assessments" did not contribute at all (pooled correlation 0.05). Multivariate analysis on the discriminant scores showed that the instruments "pain spine", "BASFI", "pain joints" and "BASDAI fatigue" explained more than 90% of variance in the case of the patient perspective. The instruments "cervical rotation", "swollen joint count", "CRP" and "intermalleolar distance" explained more than 90% of variance in case of physician perspective.
CONCLUSION: AS patients rate disease activity on the basis of complaints while physicians rate disease activity on the basis of instruments related to disease severity and inflammation.

Entities:  

Mesh:

Year:  2005        PMID: 15757962     DOI: 10.1093/rheumatology/keh595

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  39 in total

1.  Tenascin-C, a biomarker of disease activity in early ankylosing spondylitis.

Authors:  Latika Gupta; Shruti Bhattacharya; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

Review 2.  The balance of tissue repair and remodeling in chronic arthritis.

Authors:  Rik Lories
Journal:  Nat Rev Rheumatol       Date:  2011-10-18       Impact factor: 20.543

3.  Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?

Authors:  Yuen Ling Elaine Au; Woon Sing Raymond Wong; Mo Yin Mok; Ho Yin Chung; Eric Chan; Chak Sing Lau
Journal:  Clin Rheumatol       Date:  2014-07-01       Impact factor: 2.980

4.  Elevated levels of serum MRP8/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease.

Authors:  Latika Gupta; Shruti Bhattacharya; Vikas Agarwal; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2016-10-13       Impact factor: 2.980

5.  Enzyme replacement therapy and extended newborn screening for mucopolysaccharidoses: opinions of treating physicians.

Authors:  David J Coman; Ian M Hayes; Veronica Collins; Margaret Sahhar; J Ed Wraith; Martin B Delatycki
Journal:  JIMD Rep       Date:  2011-06-22

6.  Positive and negative affective states and disease activity in ankylosing spondylitis.

Authors:  Carlos Jesús Delgado Domínguez; Pilar Font Ugalde; Desireé Ruiz Vilchez; Hugo Carretero-Dios; Eduardo Collantes Estévez
Journal:  Rheumatol Int       Date:  2014-08-15       Impact factor: 2.631

7.  Early spondyloarthropathy: scintigraphic, biological, and clinical findings in MRI-positive patients.

Authors:  Orhan Akdeniz; Gamze Alayli; Fevziye Canbaz Tosun; Bariş Diren; Kivanç Cengiz; Mustafa Bekir Selçuk; Tevfik Sünter; Ferhan Cantürk
Journal:  Clin Rheumatol       Date:  2007-09-15       Impact factor: 2.980

8.  The relationship between enthesitis indices and disease activity parameters in patients with ankylosing spondylitis.

Authors:  Filiz Sivas; Bedriye Mermerci Başkan; Esra Erkol Inal; Lale Akbulut Aktekin; Nurdan Barça; Kürşat Ozoran; Hatice Bodur
Journal:  Clin Rheumatol       Date:  2008-10-24       Impact factor: 2.980

9.  Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  H Bodur; S Ataman; L Akbulut; D Evcik; V Kavuncu; T Kaya; R Günaydin; B Kuran; N Kotevoğlu; A Bal; E Aydoğ; Z Altay; H Uğurlu; H Kocabaş; N Olmez; P Yazgan; S Gürsoy; E Madenci; S Ozel; S U Delialioğlu
Journal:  Clin Rheumatol       Date:  2008-03-21       Impact factor: 2.980

10.  A prospective study of novel disease activity indices for ankylosing spondylitis.

Authors:  T G Sundaram; Hafis Muhammed; Amita Aggarwal; Latika Gupta
Journal:  Rheumatol Int       Date:  2020-08-05       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.